NCT01299298已完成1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Maximum plasma concentration (Cmax)
研究概览
简要总结
This Phase 1 study is being conducted to evaluate 3 increasing subcutaneous (SC) doses (50, mg, 100 mg or 200mg) of mipomersen in Japanese healthy volunteers. Eligible subjects will receive a single study injection of either mipomersen or placebo. Subjects will be enrolled into 1 of 3 treatment cohorts (Cohorts A, B, and C) in a dose-escalation design. Dose-escalation will proceed only if there is an acceptable safety profile from the previous dosing level.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •First generation Japanese (born in Japan of Japanese parents and Japanese grandparents), lived no more than 5 years outside of Japan, with no significant change in lifestyle or habits, including diet, while living outside of Japan.
- •Surgically sterile, abstinent or subject or partner compliant with acceptable contraceptive during and 24 weeks after the last study drug dose
- •Body weight >50 kg and body mass index between 18 and 30 kg/m2 inclusive
排除标准
- •Clinically significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, infectious, or psychiatric disease
- •Clinically significant abnormal findings on the physical examination, ECG, blood pressure, heart rate, medical history, or clinical laboratory results at Screening or before dosing
- •Positive test for human immunodeficiency virus (HIV), hepatitis B or C.
- •High sensitivity C-reactive protein (hsCRP) >5 mg/L
- •History of or current malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for > 1 year)
- •Evidence of acute or ongoing chronic inflammatory condition or infection
- •History of rash, impetigo, or drug allergies
- •Alcohol and/or drug abuse
- •Smoking more than 10 cigarettes per day
- •Planned dental work up to and including Day 8 procedures
- •Treatment with another investigational drug, biological agent, or device within 4 weeks of Screening or 5 half-lives of the study agent, whichever is longer
- •Use of prescribed medications within 4 weeks or over-the counter medications (including dietary supplements and herbal remedies) within 14 days before the first study drug dose, or use of any concomitant medications (prescribed or over the counter) through Day 8 of the study without Investigator and Sponsor approval. Vaccinations are not allowed beginning 3 weeks prior to the first dose of study drug until completion of the safety follow-up period
- •Previous exposure to oligonucleotide-based drug therapy
- •Donated 50 to 499 mL of blood within 30 days prior to consent, or >499 mL within 60 days
研究组 & 干预措施
mipomersen
Experimental
50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
干预措施: mipomersen (Drug)
placebo
Placebo Comparator
50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
干预措施: placebo (Drug)
结局指标
主要结局
Maximum plasma concentration (Cmax)
时间窗: Baseline up to Day 36 Post-Treatment
plasma PK parameters
Time to maximal concentration (Tmax)
时间窗: Baseline up to Day 36 Post-Treatment
plasma PK parameters
Area Under the Curve (AUC)
时间窗: Baseline up to Day 36 Post-Treatment
plasma PK parameters
次要结局
- Number of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)(Up to Day 36 Post-Treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisC3GIC-MPGNC3 GlomerulopathyC3 GlomerulonephritisComplement 3 GlomerulopathyComplement 3 Glomerulopathy (C3G)Complement 3 GlomerulonephritisMembranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)DDDDense Deposit DiseaseMembranoproliferative GlomerulonephritisNCT05067127Apellis Pharmaceuticals, Inc.124
已完成
3 期
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT02504645ImmuPharma202
已完成
1 期
A Study of Injection HB0017 in Adult Healthy VolunteersHealthy SubjectsNCT04505033Huabo Biopharm Co., Ltd.40
已完成
3 期
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema (HAE)NCT02584959Shire75
已完成
2 期
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese SubjectsOverweightObesityNCT00444561AstraZeneca184